CA2198119A1 - Methodes pour prevenir l'hyperplasie primaire de d'endometre - Google Patents
Methodes pour prevenir l'hyperplasie primaire de d'endometreInfo
- Publication number
- CA2198119A1 CA2198119A1 CA002198119A CA2198119A CA2198119A1 CA 2198119 A1 CA2198119 A1 CA 2198119A1 CA 002198119 A CA002198119 A CA 002198119A CA 2198119 A CA2198119 A CA 2198119A CA 2198119 A1 CA2198119 A1 CA 2198119A1
- Authority
- CA
- Canada
- Prior art keywords
- endometrial
- endometrial cancer
- compound
- biopsy
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Le procédé enrayant le cancer de l'utérus de la présente invention consiste à administrer à un être humain le nécessitant une dose efficace d'un composé représenté par la formule générale (I) ou de l'un de ses sels ou solvates pharmaceutiquement acceptables. Dans cette formule générale (I) R?1¿ et R?3¿ représentent indépendamment hydrogène, -CH¿3?, (a), ou (b), où Ar représente un phényle éventuellement substitué. R?2¿ appartient au groupe constitué de pyrrolidine, hexaméthylèneimino et pipéridino.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29385394A | 1994-08-22 | 1994-08-22 | |
US08/293,853 | 1994-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2198119A1 true CA2198119A1 (fr) | 1996-02-29 |
Family
ID=23130867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002198119A Abandoned CA2198119A1 (fr) | 1994-08-22 | 1995-08-21 | Methodes pour prevenir l'hyperplasie primaire de d'endometre |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0777476A4 (fr) |
JP (1) | JPH10504824A (fr) |
KR (1) | KR970705387A (fr) |
AU (1) | AU688112B2 (fr) |
CA (1) | CA2198119A1 (fr) |
CZ (1) | CZ51897A3 (fr) |
FI (1) | FI970717A (fr) |
HU (1) | HUT76890A (fr) |
IL (1) | IL115022A (fr) |
MX (1) | MX9701327A (fr) |
MY (1) | MY113757A (fr) |
NO (1) | NO970783L (fr) |
NZ (1) | NZ292017A (fr) |
RU (1) | RU2161964C2 (fr) |
TW (1) | TW404834B (fr) |
WO (1) | WO1996005833A1 (fr) |
ZA (1) | ZA956994B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
CN115825414B (zh) * | 2023-01-09 | 2023-04-25 | 中国医学科学院北京协和医院 | 血液或尿液代谢标志物及其在子宫内膜癌早筛中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
BR9406616A (pt) * | 1993-04-07 | 1996-02-06 | Ligand Pharm Inc | Método para triagem de agonistas receptores |
HUT71237A (en) * | 1993-10-15 | 1995-11-28 | Lilly Co Eli | Pharmaceutical compositions for treating resistant neoplasms containing 2-phenyl-3-aroil-benzotiophene derivatives and process for their preparation |
DE69520741T2 (de) * | 1994-08-22 | 2001-10-11 | Lilly Co Eli | Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der primären endometriumhyperplasie |
US5843964A (en) * | 1994-09-22 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting endometrial mitoses |
-
1995
- 1995-08-21 KR KR1019970701095A patent/KR970705387A/ko not_active Application Discontinuation
- 1995-08-21 EP EP95930243A patent/EP0777476A4/fr not_active Withdrawn
- 1995-08-21 JP JP8508265A patent/JPH10504824A/ja active Pending
- 1995-08-21 MY MYPI95002449A patent/MY113757A/en unknown
- 1995-08-21 AU AU33700/95A patent/AU688112B2/en not_active Ceased
- 1995-08-21 WO PCT/US1995/010651 patent/WO1996005833A1/fr not_active Application Discontinuation
- 1995-08-21 CA CA002198119A patent/CA2198119A1/fr not_active Abandoned
- 1995-08-21 NZ NZ292017A patent/NZ292017A/en unknown
- 1995-08-21 ZA ZA9506994A patent/ZA956994B/xx unknown
- 1995-08-21 MX MX9701327A patent/MX9701327A/es unknown
- 1995-08-21 IL IL11502295A patent/IL115022A/xx not_active IP Right Cessation
- 1995-08-21 HU HU9701499A patent/HUT76890A/hu unknown
- 1995-08-21 RU RU97104160/14A patent/RU2161964C2/ru active
- 1995-08-21 CZ CZ97518A patent/CZ51897A3/cs unknown
- 1995-08-21 TW TW084108700A patent/TW404834B/zh not_active IP Right Cessation
-
1997
- 1997-02-20 FI FI970717A patent/FI970717A/fi unknown
- 1997-02-20 NO NO970783A patent/NO970783L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0777476A4 (fr) | 1999-06-23 |
ZA956994B (en) | 1997-02-21 |
AU3370095A (en) | 1996-03-14 |
RU2161964C2 (ru) | 2001-01-20 |
HUT76890A (en) | 1997-12-29 |
FI970717A0 (fi) | 1997-02-20 |
NZ292017A (en) | 2000-07-28 |
TW404834B (en) | 2000-09-11 |
CZ51897A3 (en) | 1997-06-11 |
MX9701327A (es) | 1997-05-31 |
KR970705387A (ko) | 1997-10-09 |
FI970717A (fi) | 1997-02-20 |
MY113757A (en) | 2002-05-31 |
JPH10504824A (ja) | 1998-05-12 |
EP0777476A1 (fr) | 1997-06-11 |
WO1996005833A1 (fr) | 1996-02-29 |
IL115022A (en) | 2000-07-31 |
NO970783D0 (no) | 1997-02-20 |
AU688112B2 (en) | 1998-03-05 |
NO970783L (no) | 1997-02-20 |
IL115022A0 (en) | 1998-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6303634B1 (en) | Methods of preventing breast cancer | |
AU688112B2 (en) | Methods of inhibiting endometrial cancer | |
US5843964A (en) | Methods of inhibiting endometrial mitoses | |
MXPA97002148A (en) | Methods to inhibit endometr mythosis | |
EP0771201B1 (fr) | Utilisation des 2-phenyle-3-aroylbenzothiophenes pour la preparation d'un medicament pour l'empechement de l'hyperplasie endometriale primaire | |
EP0729755A2 (fr) | 2-Phényl-3-aroylbenzothiophènes pour inhiber le cancer des ovaires | |
US20040167170A1 (en) | Methods of preventing breast cancer | |
AU2124097A (en) | Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors) | |
WO1997026877A1 (fr) | Methode pour reduire les tumeurs du colon | |
CA2244112A1 (fr) | Methode pour reduire les tumeurs du colon | |
MXPA97006520A (en) | Methods to inhibit the ova cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |